Biohaven Pharmaceutical Holding Price to Book Ratio 2016-2021 | BHVN

Historical price to book ratio values for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The current price to book ratio for Biohaven Pharmaceutical Holding as of December 07, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Biohaven Pharmaceutical Holding Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-12-06 100.24 0.00
2021-09-30 138.91 $-9.03 -15.38
2021-06-30 97.08 $-7.00 -13.87
2021-03-31 68.35 $-4.28 -15.99
2020-12-31 85.71 $-6.49 -13.21
2020-09-30 65.01 $-3.58 -18.15
2020-06-30 73.11 $-0.60 -122.71
2020-03-31 34.03 $2.09 16.29
2019-12-31 54.44 $-0.17 -324.05
2019-09-30 41.72 $2.28 18.31
2019-06-30 43.79 $3.63 12.08
2019-03-31 51.47 $2.19 23.49
2018-12-31 36.98 $3.41 10.83
2018-09-30 37.55 $1.63 22.97
2018-06-30 39.52 $2.96 13.33
2018-03-31 25.76 $2.79 9.22
2017-12-31 26.98 $3.66 7.37
2017-09-30 37.38 $4.35 8.60
2017-06-30 25.00 $5.37 4.66
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.887B $0.064B
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $126.808B 8.01
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.211B 20.68
Arcus Biosciences (RCUS) United States $3.210B 0.00
Emergent Biosolutions (EBS) United States $2.270B 8.16
Myovant Sciences (MYOV) United Kingdom $1.508B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.469B 0.00
Zymeworks (ZYME) Canada $0.850B 0.00
SQZ Biotechnologies (SQZ) United States $0.326B 0.00
Ambrx Biopharma (AMAM) United States $0.322B 0.00
Enzo Biochem (ENZ) United States $0.170B 16.71